ADC Quality Assurance &
Potent Compound GMP Compliance
Build quality systems that support the biologic and potent small-molecule parts of
ADC manufacturing, testing, release, and lifecycle change.
Additional ADC QA Services
- Inspection readiness for contained ADC manufacturing sites
- Change notification review for linker-payload and payload suppliers
- Cross-site comparability governance during tech transfer
- OOS and OOT review for ADC analytical programs
- Product quality review inputs tailored to conjugated biologics
- Batch release board support for late-stage and commercial programs
ADC Quality Assurance Ensuring Compliance & Product Integrity Across ADC Operations
ADC quality assurance needs to cover both biological GMP requirements and potent compound control. DES Pharma supports QA systems built for that combined risk profile, where product quality depends not only on antibody integrity and microbiological control, but also on controlled conjugation, containment, cleaning effectiveness, residual free payload limits, and disciplined change management.
We help sponsors build phase-appropriate QA systems for ADC manufacturing, testing, storage, and external oversight. That includes supplier qualification, occupational safety coordination, batch record review, deviation and CAPA management, inspection preparation, comparability governance, and batch release strategy. The goal is to align the quality system with real product risks, the analytical control approach, and the partner network from early clinical supply through commercial operations.
ADC QA System & Compliance Focus Areas
Where quality controls most often affect ADC execution and filing readiness
Our focus areas: potent compound GMP systems, cleaning validation, batch disposition logic, quality agreements, change control, and comparability oversight.
Quality Assurance Systems
Smart, Efficient Operations
ADC QA System Coverage
Comprehensive quality assurance across every function that touches ADC product quality — from supplier qualification and deviation management through batch release and inspection readiness.
Supplier Management &
Qualification
- Qualification of antibody, linker-payload, payload, and conjugation reagent suppliers
- Quality agreements covering potent compound change control, traceability, and investigation timelines
- Audit planning for contained manufacturing sites and specialized testing partners
- Material classification and status control for high-risk and high-potency inputs
- Vendor oversight for outsourced analytical testing of DAR, free payload, and potency
- Escalation pathways for supplier deviations with direct product quality impact
Auditing & Assessment
Systems
- Internal and external audit plans built around ADC-specific GMP and containment risks
- Readiness checks for cleaning validation, line clearance, and potent compound waste handling
- Inspection support for batch genealogy, change history, and analytical data traceability
- CAPA governance for cross-functional issues involving production, QC, EHS, and supply chain
- Data integrity review of chromatographic and mass spectrometric release testing systems
- Management review metrics focused on deviation recurrence and control strategy performance
Material Quality
Management
- Release and disposition workflows for antibody bulk, linker-payload, and finished ADC intermediates
- Sampling controls that protect personnel and sample integrity for potent materials
- Status labeling, reconciliation, and controlled destruction procedures for cytotoxic materials
- Review of certificates, residual impurity data, and transport conditions before release to use
- Retest and expiry governance for reactive reagents and limited-life materials
- Reference standard governance for ADC lots, conjugated controls, and payload standards
Manufacturing Operations QA
- Batch record review for reduction, conjugation, quench, purification, and hold-step control
- Deviation investigations tied to DAR shifts, aggregation, free payload excursions, and yield loss
- Change control for antibody source, linker-payload lot, reaction conditions, and scale
- Cleaning validation oversight for shared or contained equipment with potent residue risk
- Training qualification for operators working with cytotoxic materials and contained processes
Technical Operations QA
- CMC documentation review for process description, control strategy, and specification rationale
- Analytical method lifecycle QA oversight under ICH Q14 and Q2(R2)
- Comparability protocol and report review for process, site, and scale changes affecting ADC quality
- Technical training and qualification for staff involved in ADC method and process decisions
QC Operations QA
- Laboratory document review for ADC release methods and stability protocols
- OOS and OOT investigation oversight for DAR, potency, free payload, and aggregate results
- Qualification and validation review for ADC-specific and platform analytical methods
- Data integrity assessments for chromatographic, mass spectrometric, and bioassay platforms
Product Quality & Release
- Batch release approval covering manufacturing, analytical, and stability review for ADC lots
- Product specification review integrating biologic and small-molecule release criteria
- COA review, disposition documentation, and exception management for ADC batches
- PQR and APR design for conjugated biologics with multi-attribute control strategies
ADC Quality Priorities ADC Quality Priorities
A good ADC QA system defines what must be controlled because it affects patient safety, product consistency, operator protection, or filing support. For ADCs, those priorities usually extend beyond standard biologic GMP into potent compound handling, cleaning validation, conjugation-related comparability, and release decisions that bring together biologic and small-molecule quality data.
Potent Compound Containment & Exposure Control
Governance for PPE requirements, containment procedures, occupational exposure band compliance, and documented oversight for all personnel working with cytotoxic ADC payloads.
Batch Release Package Design
Integrated review of DAR distribution, potency, purity, residual free payload, and stability data, structured so the disposition decision is supported by complete and traceable records.
Cleaning Validation Strategy
Oversight for cleaning validation of shared or dedicated equipment with cytotoxic material risk, including worst-case product selection, swab method suitability, and carryover limit justification.
Stability Program Governance
Quality oversight for stability protocols monitoring linker integrity, payload retention, aggregate formation, and potency maintenance, with trending review and out-of-trend investigation procedures.
Comparability Assessment
Quality governance for process changes affecting DAR distribution, potency profile, or purity, including comparability protocol design, data review, and regulatory filing impact assessment. Pertained appropriately, and the batch record tells the full story.
Cross-Functional QA Oversight
Quality systems that span EHS, manufacturing, analytics, and supply chain, so containment controls, deviation investigations, change reviews, and supplier events are managed as one integrated risk picture.
ADC QA Expertise Quality Systems Built Around Real ADC Operations
ADC QA works best when it stays close to how the product is actually made and tested. DES Pharma helps sponsors build quality systems that reflect batch execution, analytical workflows, and outsourcing models rather than generic templates. We pay particular attention to the areas that can become inspection or release bottlenecks in ADC programs, including potent compound controls, cleaning and segregation logic, external partner oversight, batch record discipline, method lifecycle governance, and decision-making around changes and comparability.
Potent Compound Quality Systems
Contained operations, training records, and documented oversight for all cytotoxic material handling activities.
Cleaning & Segregation Planning
Carryover risk assessment, campaign management logic, and changeover expectations for ADC manufacturing equipment.
Batch Disposition Workflows
Review structures that support complete and timely disposition decisions for complex ADC release packages.
Partner Quality Governance
Oversight across manufacturers, testing labs, and logistics providers, with quality agreements matched to the risk profile of each relationship.
Inspection Preparation Inspection-Ready Before It Becomes Urgent
DES Pharma helps ADC sponsors prepare inspection-facing records, governance summaries, and quality narratives before the inspection window, so responses are prepared, not improvised.
- Batch record traceability reviews for conjugation, purification, and release data
- Change history summaries with control strategy impact documentation
- Cleaning validation and potent compound program documentation reviews
- Analytical data integrity gap assessments for ADC release and stability systems
- Response support for FDA Form 483 observations and warning letter remediation
Why DES Pharma for ADC QA
Robust QA Processes
Supporting
Reliable Outcomes
Quality systems designed for how ADC programs actually operate — not adapted from general biologics templates.
Practical Compliance
Quality systems designed to work in day-to-day manufacturing, testing, and partner management, not only to satisfy a checklist on paper or during an audit.
ADC-Focused Oversight
Quality thinking that reflects both the biologic and the potent small-molecule character of ADC products, across manufacturing, testing, storage, and distribution.
Cross-Functional Alignment
QA integrated across manufacturing, analytics, supply, and EHS, so deviation investigations, change reviews, and supplier events are managed with a complete risk picture.
Faster Issue Handling
Deviation, CAPA, and change control pathways designed to reach decisions more quickly, with appropriate documentation depth and cross-functional involvement built in from the start.
Release Confidence
Batch release structures supported by well-organized review packages, clear disposition criteria, and complete traceability, so release decisions are well-founded and defensible.
Lifecycle Durability
Quality systems built to remain functional through scale-up, PPQ, commercial launch, and post-approval change, not designed for one stage and then requiring reconstruction at the next.
Our ApproachADC QA Operating Model
A six-step framework for building quality systems that reflect real ADC operations, support timely decisions, and stay functional from clinical through commercial stage.
Define Critical Quality Responsibilities
Map QA accountabilities across internal teams and external partners (including manufacturers, testing labs, payload suppliers, and logistics providers) to eliminate gaps in oversight.
Set Document & Data Review Pathways
Design batch record, analytical data, and documentation review workflows that support timely disposition decisions without creating bottlenecks or incomplete review trails.
Embed Risk Management
Apply ICH Q9-aligned risk assessment into supplier oversight, deviation investigation prioritization, CAPA planning, and change control evaluation for ADC-specific risk factors.
Connect Events to Product Quality
Link manufacturing deviations, analytical anomalies, and supply events back to product quality impact assessment, so QA decisions are grounded in patient safety, not just procedural compliance.
Prepare Inspection-Facing Records in Advance
Build governance summaries, batch genealogy narratives, and quality system documentation before inspection pressure, so health authority reviews are supported by organized, complete records.
Review Trends Proactively
Maintain regular management review, PQR, and APR cycles with ADC-relevant metrics so commercial quality oversight catches drift and recurrence patterns before they become deviation investigations.
Get Started Build ADC Quality Systems That Support Compliance, Release, and Day-to-Day Execution.
Connect with our QA team to discuss potent compound GMP systems, cleaning validation, batch release strategy, or inspection readiness for your ADC program.